Penyakit Katup Jantung

Aminah Dalimunthe

Farmakoterapi Sistem Kardiovaskular 1

Farmakoterapi Sistem Kardiovaskular 2
Farmakoterapi Sistem Kardiovaskular 3
 KATUP JANTUNG
•2 daun katup
MITRALIS • antara atrium kiri dg ventrikel kiri

•3 daun katup
TRIKUSPIDALIS •antara atrium kanan dg ventrikel kanan

SEMILINARIS PULMONALIS •antara ventrikel kanan dg arteri pulmonalis

SEMILUNALIS AORTA •antara ventrikel kiri dg aorta

 AHA

5 juta orang Amerika

didiagnosis penyakit jantung
katup setiap tahun

Farmakoterapi Sistem Kardiovaskular 5

KLASIFIKASI

Farmakoterapi Sistem Kardiovaskular 6

Stenos •Katup membuka lebih kecil
dr normal karena menyatu

is atau kaku

Insufisie •Regurgitasi, kebocoran

katup
nsi katup •Katup tidak tertutup rapat

Farmakoterapi Sistem Kardiovaskular 7

Sifilis Bawaan
Penyeba
b
Penyakit jantung : Demam
kardiomiopati,
penyakit arteri rematik/End
koroner, HTN okarditis

Radiasi
Farmakoterapi Sistem Kardiovaskular 8
Farmakoterapi Sistem Kardiovaskular 9
 Gejala
Ѽ Sesak nafas
Ѽ Lemah
Ѽ Pusing
Ѽ Nyeri dada
Ѽ Berdebar-debar
Ѽ Pembengkakan pada pergelangan kaki,
kaki atau perut

Farmakoterapi Sistem Kardiovaskular 10

Echocardiographic criteria for the definition of
severe valve stenosis: an integrative approach

Farmakoterapi Sistem Kardiovaskular 11

Echocardiographic criteria for the definition of severe valve regurgitation:
an integrative approach

Farmakoterapi Sistem Kardiovaskular 12

Farmakoterapi Sistem Kardiovaskular 13
Farmakoterapi Sistem Kardiovaskular 14
 Medical Therapy
Patients who are unsuitable candidates for
surgery or TAVI—or who are currently
awaiting a surgical or TAVI procedure—may be
treated with digoxin, diuretics, ACE inhibitors,
or ARBs if they experience HF symptoms.
Co-existing hypertension should be treated.

Farmakoterapi Sistem Kardiovaskular 15

 Management after valve
replacement

• A complete baseline assessment should,

ideally, be performed 6–12 weeks after
surgery.
• Clinical assessment : chest X-ray, ECG, and
blood testing.

Farmakoterapi Sistem Kardiovaskular 16

• Antithrombotic management : low-dose
aspirin ((≤100 mg daily)
• Management of haemolysis and paravalvular
leak : iron supplementation, beta-blockers and
erythropoietin
• Management of valve thrombosis :
intravenous recombinant tissue plasminogen
activator 10 mg bolus + 90 mg in 90 minutes
with UFH, or streptokinase 1 500 000 U in 60
minutes without UFH.
Farmakoterapi Sistem Kardiovaskular 17
 Management during
non-cardiac surgery

• Cardiovascular morbidity and mortality is

increased in patients with VHD (mainly severe
VHD) who undergo non-cardiac surgery.

Farmakoterapi Sistem Kardiovaskular 18